A single infusion reversed new-onset type 1 diabetes (T1D) in more than half of treated mice by strengthening regulatory T cells and driving autoreactive CD8+ T cells into a less destructive state.
|Articles|July 13, 2018
New Clinical Trial Results Highlight AJPB Week in Review
Author(s)AJPB staff
Top news of the week from The American Journal of Pharmacy Benefits.
Advertisement
5. Combination Treatment Misses Overall Survival Endpoint in Breast Cancer Trial
In the phase 3 PALOMA-3 trial, Pfizer’s palbociclib (Ibrance) narrowly missed reaching its secondary endpoint of overall survival (OS), according to a press release. Read more.
4. Review: Time from Symptom Onset to Multiple Myeloma Diagnosis Can Be Reduced
Currently, many patients experience a more than 3-month delay until their diagnosis is confirmed. Read more.
3. FDA Updates Fluoroquinolone Labeling to Strengthen Mental Health, Hypoglycemia Risks
Officials with the FDA are requiring safety label updates for fluoroquinolone antibiotics due to risks of mental health adverse effects and blood sugar disturbances, according to a press release. Read more.
2. Experimental HIV Vaccine Induces Robust Immune Response in Humans
An experimental HIV-1 vaccine regimen was well-tolerated and produced immune responses against HIV in humans and rhesus monkeys. Read more.
1. Investigational Drug for Alzheimers Disease Achieves Key Endpoints in Phase 2 Trial
Positive topline results from Study 201, a phase 2 study of BAN2401, an investigational Alzheimer Disease (AD) therapy, have been announced by Eisai Co. and Biogen. Read more.
Advertisement
Related to this article
A detailed LINKER-MM1 analysis found that cytokine release syndrome (CRS) with linvoseltamab occurred early, was predominantly low grade, and became less frequent with successive step-up and full doses.
Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
In a Pharmacy Times interview, study coauthor William J. Peppard, PharmD, discusses the association between suzetrigine and fewer opioid refills after knee replacement, the limits of the evidence, and the access barriers pharmacists can help patients navigate.
The once-daily tablet is the third approved treatment for fibrodysplasia ossificans progressiva (FOP), with CYP3A4 and metformin interaction guidance.
Novo's topline phase 3 data show 12.4% weight loss with CagriSema 1.0 mg/1.0 mg in type 2 diabetes and 21.0% in adults with overweight or obesity.
Marissa Reigelman of US Pharmacopeia explains how single-country dependence on key starting materials, combined with low prices, has kept 5 critical injectable drugs in shortage for more than a decade.
An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-quarters of treated patients.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Tavapadon, First D1/D5 Agonist for Parkinson Disease
2
Ramantamig's 93.6% ORR and Outpatient CRS Control
3
CagriSema Tops Tirzepatide 5 mg for Weight Loss in REIMAGINE 5
4
Engineered Stem Cell Therapy Reverses New-Onset T1D in Mice by Reprogramming T Cells
5